Background
COVID-19 disease
VIRUS, VIRAL DISEASES, DISEASE, DISEASES, SEVERE ACUTE RESPIRATORY SYNDROME
COVID-19 first appeared in China in early 2020 and quickly spread all around the world. This eventually made the World Health Organization (WHO) formally declare the disease as a “Global Pandemic” in March 2020. The virus that causes COVID-19 disease is called severe acute respiratory syndrome virus No. 2 (SARS-CoV-2) [The available therapeutic interventions for COVID-19 can be classified as antiviral drugs, anti-inflammatory drugs, monoclonal antibodies, and plasma therapy, the efficacy of which is being studied in various clinical studies [Microelements are vital elements whose metabolism modifications substantially affect the immune system responses [Over the last decade, studies on the structures synthesized based on nanochelating technology have demonstrated the therapeutic effects of these medicines in cellular and animal models of various diseases [Given the established role of iron and selenium metabolism in the immune system responses and outcomes of viral diseases, the current study aimed to assess the impact of adding the combination of BCc1 (having iron-chelating property) and Hep-S (selenium-containing) nanomedicines to the standard treatment of hospitalized COVID-19 patients.